Galectin Therapeutics Inc. [NASDAQ: GALT] closed the trading session at $3.78 on 05/03/21. The day’s price range saw the stock hit a low of $3.75, while the highest price level was $4.43. The company report on April 27, 2021 that Galectin Therapeutics to Present at 4th Global NASH Congress.
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced that Pol F. Boudes, M.D., Chief Medical Officer, will present the belapectin program at the 4th Global NASH Congress taking place virtually on April 28 and 29, 2021.
On Thursday, April 29th, Dr. Boudes will review Galectin Therapeutics’ scientific and clinical activities in NASH cirrhosis, followed by a Q&A session. Only registered attendees are able to view the presentation. Additional details can be found below:.
The stocks have a year to date performance of 68.75 percent and weekly performance of -13.50 percent. The stock has been moved at 44.83 percent over the last six months. The stock has performed 71.82 percent around the most recent 30 days and changed 81.73 percent over the most recent 3-months.
If compared to the average trading volume of 2.46M shares, GALT reached to a volume of 1669089 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Galectin Therapeutics Inc. [GALT]:
H.C. Wainwright have made an estimate for Galectin Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 13, 2020. While these analysts kept the previous recommendation, B. Riley FBR raised their target price to Buy. The new note on the price target was released on February 13, 2019, representing the official price target for Galectin Therapeutics Inc. stock. Previously, the target price had yet another raise from $6 to $10, while H.C. Wainwright kept a Buy rating on GALT stock. On November 28, 2017, analysts increased their price target for GALT shares from 3.50 to 6.
The Average True Range (ATR) for Galectin Therapeutics Inc. is set at 0.58 The Price to Book ratio for the last quarter was 9.95, with the Price to Cash per share for the same quarter was set at 0.49.
GALT stock trade performance evaluation
Galectin Therapeutics Inc. [GALT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -13.50. With this latest performance, GALT shares gained by 71.82% in over the last four-week period, additionally plugging by 44.83% over the last 6 months – not to mention a rise of 40.00% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GALT stock in for the last two-week period is set at 56.64, with the RSI for the last a single of trading hit 53.97, and the three-weeks RSI is set at 57.53 for Galectin Therapeutics Inc. [GALT]. The present Moving Average for the last 50 days of trading for this stock 2.61, while it was recorded at 4.34 for the last single week of trading, and 2.60 for the last 200 days.
Galectin Therapeutics Inc. [GALT]: An insightful look at the core fundamentals
Return on Total Capital for GALT is now -67.05, given the latest momentum, and Return on Invested Capital for the company is -67.19. Return on Equity for this stock declined to -67.25, with Return on Assets sitting at -60.12. When it comes to the capital structure of this company, Galectin Therapeutics Inc. [GALT] has a Total Debt to Total Equity ratio set at 0.21. Additionally, GALT Total Debt to Total Capital is recorded at 0.21, with Total Debt to Total Assets ending up at 0.18. Long-Term Debt to Equity for the company is recorded at 0.04, with the Long-Term Debt to Total Capital now at 0.03.
Reflecting on the efficiency of the workforce at the company, Galectin Therapeutics Inc. [GALT] managed to generate an average of -$3,910,833 per employee.Galectin Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.50 and a Current Ratio set at 5.50.
Earnings per share (EPS) analysis for Galectin Therapeutics Inc. [GALT] stock
With the latest financial reports released by the company, Galectin Therapeutics Inc. posted -0.06/share EPS, while the average EPS was predicted by analysts to be reported at -0.09/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 33.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GALT.
Galectin Therapeutics Inc. [GALT]: Insider Ownership positions
There are presently around $46 million, or 17.80% of GALT stock, in the hands of institutional investors. The top three institutional holders of GALT stocks are: BLACKROCK INC. with ownership of 2,598,089, which is approximately 3.794% of the company’s market cap and around 11.60% of the total institutional ownership; VANGUARD GROUP INC, holding 1,880,527 shares of the stock with an approximate value of $8.31 million in GALT stocks shares; and ADVISOR GROUP HOLDINGS, INC., currently with $4.84 million in GALT stock with ownership of nearly 5.807% of the company’s market capitalization.
Positions in Galectin Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 32 institutional holders increased their position in Galectin Therapeutics Inc. [NASDAQ:GALT] by around 687,177 shares. Additionally, 21 investors decreased positions by around 382,038 shares, while 25 investors held positions by with 9,228,905 shares. The mentioned changes placed institutional holdings at 10,298,120 shares, according to the latest SEC report filing. GALT stock had 11 new institutional investments in for a total of 245,547 shares, while 2 institutional investors sold positions of 43,640 shares during the same period.